Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL

Cancer Research - United States
doi 10.1158/0008-5472.can-08-4490
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Pharmacologic Inhibition of mTOR Improves Lapatinib Sensitivity in HER2-Overexpressing Breast Cancer Cells With Primary Trastuzumab Resistance

Anti-Cancer Agents in Medicinal Chemistry
Cancer ResearchMolecular MedicinePharmacology
2012English

Effects of Herceptin on Circulating Tumor Cells in HER2 Positive Early Breast Cancer

Genetics and Molecular Research
MedicineGeneticsMolecular Biology
2015English

Novel HER2 Aptamer Selectively Delivers Cytotoxic Drug to HER2-positive Breast Cancer Cells in Vitro

Journal of Translational Medicine
BiochemistryMedicineGeneticsMolecular Biology
2012English

Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer

International Journal of Breast Cancer
Cancer ResearchOncologyPharmacology
2012English

HER2-positive Breast Cancer With Brain Metastasis, Long Responder to Lapatinib Therapy

AboutOpen
2018English

A Nanobody Activation Immunotherapeutic That Selectively Destroys HER2-Positive Breast Cancer Cells

ChemBioChem
Organic ChemistryBiochemistryMolecular MedicineMolecular Biology
2015English

Detection of HER2-positive Circulating Tumor Cells Using the LiquidBiopsy® System in Breast Cancer

Clinical Breast Cancer
Cancer ResearchOncology
2019English

A Novel Asymmetrical Anti-Her2/Cd3 Bispecific Antibody Exhibits Potent Cytotoxicity for HER2-positive Tumor Cells

Journal of Experimental and Clinical Cancer Research
Cancer ResearchOncology
2019English

Patient With Metastatic Breast Cancer, HER2-positive, Trastuzumab- And Pertuzumab-Resistant Responding to Lapatinib

AboutOpen
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy